The first patient to receive the Russian cancer vaccine saw the disappearance of metastases, according to the Ginsburg Academy.

The first patient to receive the Russian cancer vaccine saw the disappearance of metastases, according to the Ginsburg Academy.

The first patient treated with the Russian-adapted cancer vaccine showed no new tumor growths after four months of follow-up, reported Alexander Ginzburg, scientific director of the Gamaliya Center.

According to the academy, the patient's metastases disappeared. His condition is monitored monthly using high-precision CT scans, paying special attention to the lymph nodes.

The Russian cancer vaccine is based on mRNA technology. The drug was developed individually based on the patient's genetic characteristics and trains the immune system to identify and destroy malignant cells.

The first patient will be followed up for three years to assess the sustainability of the treatment results. Caravans: